Etoposide

• Catalog No.: Bio-0037
• CAS Number: 33419-42-0
• M. F.: C29H32O13
• M. W.: 588.55658

SYNONYMS

• IUPAC name: (10R,11R,15R,16S)-16-{[(2R,4aR,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^3,^7.0^1^1,^1^5]hexadeca-1,3(7),8-trien-12-one
• IUPAC Traditional name: (10R,11R,15R,16S)-16-{[(2R,4aR,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^3,^7.0^1^1,^1^5]hexadeca-1,3(7),8-trien-12-one
• Synonyms: Etopophos; Citodox; Vepesid; Vepeside; Exitop; Vespid; Abiposid; Amizide; Toposar

DATABASE IDS

• CAS Number: 33419-42-0

PROPERTIES

• Application(s): Antineoplastic agent
• Mechanism of Action: DNA topoisomerase II inhibitor

REFERENCES

• Keller-Juslen, C. et al., J. Med. Chem., 1971, 14, 936, (synth, pharmacol)
• Arnold, A.M. et al., Lancet, 1981, 2, 912, (rev)
• Issell, B.F. et al., Etoposide (VP-16): Curr. Status New Dev. [Pap. Symp], (Eds.), Academic Press, 1984, (book)
• Clark, P.I. et al., Clin. Pharmacokinet., 1987, 12, 223, (rev, pharmacol, metab, tox)
• Holthuis, J.J.M. et al., Anal. Profiles Drug Subst., 1989, 18, 121, (rev)
• Sthelin, H.F. et al., Prog. Drug Res., 1989, 33, 169, (rev)
• Sthelin, H.F. et al., Cancer Res., 1991, 51, 5, (rev)
• Semin. Oncol., Suppl. 13, 1992, 19, (rev)
• von Wartburg, A. et al., Chron. Drug Discovery, 1993, 3, 349, (rev)
• Cragg, G. et al., Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents, (ed. Powis, G.), Pergamon Press, 1994, 364, (rev)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 7th edn., Akademie-Verlag, 1994, 10960, (synonyms)
• Hainsworth, J.D. et al., Ann. Oncol., 1995, 6, 325, (pharmacol, rev)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 532
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, EAV500